Related Experiment Video
Updated: Mar 3, 2026

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition
Sabbir Khan1, Sandeep K Komarya1, Gopabandhu Jena1
1Facility for Risk Assessment & Intervention Studies, Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education & Research, Sector-67, SAS Nagar, Punjab-160062, India.
Insights
Phenylbutyrate (PBA), an FDA-approved drug, shows promise for treating diabetes by reducing endoplasmic reticulum (ER) stress and inhibiting histone deacetylases (HDACs). This approach may improve beta-cell function and insulin resistance, offering a new therapeutic avenue.
Area of Science:
- Endocrinology
- Pharmacology
- Molecular Biology
Background:
- Global diabetes incidence is rising, driven by genetic and epigenetic factors.
- Endoplasmic reticulum (ER) stress and histone deacetylases (HDACs) play critical roles in beta-cell dysfunction and insulin resistance.
- Phenylbutyrate (PBA) is an FDA-approved drug known to inhibit HDACs and reduce ER stress.
Purpose of the Study:
- To review the potential of Phenylbutyrate (PBA) as a therapeutic agent for diabetes.
- To explore PBA's mechanisms of action, including ER stress inhibition and HDAC inhibition.
- To evaluate PBA's impact on beta-cell function and insulin resistance.
Main Methods:
- Review of existing scientific literature on PBA, ER stress, HDACs, and diabetes.
- Analysis of studies investigating PBA's effects on cellular pathways related to diabetes.
- Synthesis of evidence regarding PBA's influence on beta-cell function and insulin resistance.
Main Results:
- Chronic ER stress contributes to beta-cell apoptosis and failure.
- HDAC inhibition by PBA can modulate key biochemical pathways.
- PBA demonstrates potential to improve beta-cell function and insulin sensitivity.
Conclusions:
- PBA's ability to inhibit ER stress and HDACs suggests a promising therapeutic strategy for diabetes.
- Further research into PBA's efficacy and safety for diabetes treatment is warranted.
- Targeting ER stress and HDACs with PBA may offer a novel approach to managing diabetes.
Abstract:
Incidences of diabetes are increasing globally due to involvement of genetic and epigenetic factors. Phenylbutyrate (PBA) is a US FDA approved drug for treatment of urea cycle disorder in children. PBA reduces endoplasmic reticulum (ER) stress and is proven as a potent histone deacetylases (HDACs) inhibitor. Chronic ER stress results in unfolding protein response, which triggers apoptosis. Abnormal ER homoeostasis is responsible for defective processing of several genes/proteins and contributes to β-cell death/failure. Accumulated evidences indicated that HDACs modulate key biochemical pathways and HDAC inhibitors improve β-cell function and insulin resistance by modulating multiple targets. This review highlights the role of PBA on β-cell functions, insulin resistance for possible treatment of diabetes through inhibition of ER stress and HDACs.
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Cell Specific Gene Expression
Insulin Secretory Vesicles
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Dipeptidyl Peptidase 4 Inhibitors
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...

